Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.
Explore this paper's citation graph
Summary
Aza C treatment results in significantly higher response rates, improved quality of life, reduced risk of leukemic transformation, and improved survival compared with supportive care.
- Type
- article
- Published
- 2002-05-15
- Cited by
- 1,828
- References
- 80
- OpenAlex
- https://openalex.org/W2106584820
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:43792291
Keywords
Medicine, Azacitidine, Randomized controlled trial, Internal medicine, Myelodysplastic syndromes
References
- Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
- Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.
- Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome.
- Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score.
- High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study.
- Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes.
- Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.
- International scoring system for evaluating prognosis in myelodysplastic syndromes.
- Erythropoietin treatment in patients with myelodysplastic syndrome and anemia.
- Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent.
- Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin.
- Effects of recombinant human granulocyte colony-stimulating factor (CSF), human granulocyte macrophage-CSF, and gibbon interleukin-3 on hematopoiesis in human long-term bone marrow culture.
- 5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia.
- Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine.
- Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome.
- Does treatment with ARA-C in low dosage cause differentiation of leukemic cells?
- A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes.
- Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine.
- Partially matched bone marrow transplantation in patients with myelodysplastic syndromes.
- Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial.
Cited by
- Loss of imprinting of IGF2 and the epigenetic progenitor model of cancer.
- Treatment strategies to optimize clinical benefit in the patient with myelodysplastic syndromes.
- DNA methylation in the immune system.
- CpG island methylator phenotype in cancer
- Clinical experience with decitabine in North American patients with myelodysplastic syndrome
- Epigenetic Therapy of Leukemia: an update
- Pharmacotherapy of myelodysplastic syndromes
- Stem cells and the aging hematopoietic system
- Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine
- Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine.
- Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura
- Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
- Treatment of higher-risk myelodysplastic syndrome.
- Epigenetic Drug Discovery
- Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes
- A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial
- Laboratory and clinical risk assessment to treat myelodysplatic syndromes
- The risk of infections in patients with myelodysplastic syndromes in 2016
- The combination of dimethoxycurcumin with DNA methylation inhibitor enhances gene re-expression of promoter-methylated genes and antagonizes their cytotoxic effect
- Demethylating Agents in the Treatment of Cancer
Related papers
- Hematology: Azacitidine improves survival in myelodysplastic syndromes
- New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.
- Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS)
- Safety and efficacy of azacitidine in myelodysplastic syndromes
- Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents.
- Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion.
- Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5‐azacitidine
- 33 Which myelodysplastic syndromes patients are candidates for treatment with azacitidine
- Comparison of the IPSS and IPSS-R in Predicting Survival and Response of Myelodysplastic Syndrome Patients to 5-Azacitidine
- Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry